PND 1186

Key Product Details

Product Description

PND 1186 is a potent FAK inhibitor (IC₅₀ values are 1.5 and 100 nM for recombinant FAK and FAK in breast carcinoma cells, respectively). Promotes caspase activation; triggering apoptosis. Inhibits 4T1 breast carcinoma subcutaneous tumor growth and breast carcinoma cell motility. Decreases spontaneous breast to lung metastasis in pre-clinical models. Orally bioavailable.

Product Specifications for PND 1186

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PND 1186

The following data is based on the product molecular weight 501.51.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.99 mL	9.97 mL	19.94 mL
5 mM	0.40 mL	1.99 mL	3.99 mL
10 mM	0.20 mL	1.00 mL	1.99 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 5 publications citing the usage of this product.

• Tanjoni PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol.Ther. 2010 PMID: 20234191
• Jiang Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat.Med. 2016 PMID: 27376576
• Walsh Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol.Ther. 2010 PMID: 20234193

Product Documents for PND 1186